For Quick Alerts
For Daily Alerts

Aurobindo Pharma Rallies As Company Gets US FDA Approval


Shares in Aurobindo Pharma was trading 2 per cent higher after the company said it has received USFDA's approval for Sildenafil Tablets, 20mg.

The product is expected to be launched by Q4 FY 2015-16. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) REVATIO (sildenafil citrate) Tablets 20 mg of Pfizer, Inc.

Aurobindo Pharma Rallies As Company Gets US FDA Approval
Aurobindo Pharma: Quotes, News
BSE 660.90BSE Quote3.95 (-0.60%)
NSE 662.00NSE Quote2.95 (-0.45%)
Sildenafil Tablets are used in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs). The approved product has an estimated market size of US$80 million for the twelve months ending September 2015 according to IMS.

This is the 51st ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 219 ANDA approvals (190 Final approvals including 10 from Aurolife Pharma LLC and 29 Tentative approvals) from USFDA.

Read more about: aurobindo pharma
Story first published: Monday, November 23, 2015, 12:10 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more